Fri, August 20, 2010
Thu, August 19, 2010
Wed, August 18, 2010
Tue, August 17, 2010
Mon, August 16, 2010
Fri, August 13, 2010
Thu, August 12, 2010
Wed, August 11, 2010
Tue, August 10, 2010
Mon, August 9, 2010
Fri, August 6, 2010
Thu, August 5, 2010
Wed, August 4, 2010
Tue, August 3, 2010
Mon, August 2, 2010
Fri, July 30, 2010
Thu, July 29, 2010
Wed, July 28, 2010

Derma Sciences Announces Second Quarter 2010 Results Conference Call


//health-fitness.news-articles.net/content/2010/ .. second-quarter-2010-results-conference-call.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


PRINCETON, N.J.--([ BUSINESS WIRE ])--Derma Sciences, Inc. (Nasdaq:DSCI), a medical device and pharmaceutical company focused on advanced wound care, will hold a conference call on August 13, 2010 to discuss the financial results for the second quarter ended June 30, 2010. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

The conference call is scheduled to begin at 11:00 a.m. EDT (Eastern Daylight Time). The results will be released before the opening of the market that same day.

To access the conference call, U.S.-based listeners should dial (888) 563-6275 and international listeners should dial (706) 643-3137. All listeners should provide the following passcode: 92702988.

Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Companya�s website, [ www.dermasciences.com ]. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast.

Following the end of the conference call, a replay will be available through August 16, 2010, and can be accessed by dialing (800) 642-1687 within the U.S. or (706) 645-9291 outside of the U.S. All listeners should provide the following passcode: 92702988. The webcast will also be available for 30 days.

About Derma Sciences, Inc.

Derma Sciences is a medical technology company focused on three segments of the wound care marketplace, traditional dressings, advanced wound care dressings and pharmaceutical wound care products. Its MEDIHONEY� product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 leg ulcer patients. Other novel products introduced into the $14 billion global wound care market include XTRASORB� for better management of wound exudates, and BIOGUARD� for infection prevention. Derma Sciences also expects to complete the efficacy portion of its Phase II clinical study with DSC127, a novel pharmaceutical for accelerated wound healing and scar reduction, by the end of 2010.

For more information please visit [ www.dermasciences.com ].


Publication Contributing Sources